Assertio Holdings, Inc. Announces Leadership Transition
LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company’s Chief Executive Officer. The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief executive.
- LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company’s Chief Executive Officer.
- The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief executive.
- “I am committed to Assertio and its employees and stakeholders, and its future success,” Ms. Mason said.
- “I will work to ensure that we are best positioned to maximize the opportunities in front of us, and to ensure a smooth leadership transition as we bring in a CEO to lead the Company into the next phase of our business.”